Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma × conatumumab × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2 Thoracic 1 Sarcoma 1 Gastrointestinal 1 Endocrine 1

Conditions

Sarcoma 1 Neoplasm Metastasis 1 Lymphoma 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoid Tumor 1

Interventions

ganitumab 1 conatumumab 1 amino-acid, glucose, and electrolyte solution 1 Fluorodeoxyglucose F18 1 Bevacizumab 1 90Y-octreotide, DOTA-Tyr(3)- 1 177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01327612 2021-02-21

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Amgen

Phase 2 Completed

12 enrolled 21 charts

EndocrineGastrointestinalLymphoidSarcomaThoracic

Carcinoid Tumor, Carcinoma, Non-Small-Cell Lung, Lymphoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡